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ABSTRACT
Introduction: Delayed-release dimethyl fumarate
(DMF; also known as gastro-resistant DMF) is an
oral agent for the treatment of relapsing forms of
multiple sclerosis (MS). No formal studies of
DMF were conducted in pregnant women,
although pregnancies have occurred during
clinical trials and in the postmarketing setting.
Methods: Preclinical developmental and
reproductive toxicology studies were
performed with DMF in rats and rabbits. As of
March 26, 2014, the DMF clinical development
program included a total of 4132 subjects
consisting of 2898 patients with MS, 320
psoriasis patients, 101 rheumatoid arthritis
patients, and 813 healthy volunteers. Subjects
were required to use reliable contraception and
immediately discontinue treatment in the event
of pregnancy.
Results: Animal studies showed no evidence of
impaired fertility or teratogenicity with DMF.
Overall as of June 30, 2014, 63 pregnancies were
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reported in clinical trials. Outcomes are known
for 39 of 42 subjects receiving DMF and include
26 live births (67%), three spontaneous
abortions (8%), and 10 elective terminations
(26%); follow-up is ongoing in 2 cases and one
patient was lost to follow-up. The incidence of
spontaneous abortion in subjects exposed to
DMF was consistent with the expected rate of
early pregnancy loss in the general population
(12–22%). A total of 135 pregnancies were
reported in the postmarketing setting
(spontaneous and solicited reports). Outcomes
are known for 30 cases and include 10 live
births, 13 spontaneous abortions, and 5 elective
terminations; follow-up is ongoing in 103 cases
and 2 patients have been lost to follow-up.
Conclusion: Although data are limited and all
known exposures have occurred in the first
trimester, no increased risk of fetal
abnormalities or adverse pregnancy outcomes
associated with gestational exposure to DMF
has been observed.
Funding: Biogen, Inc.
Keywords: Clinical trial; Delayed-release
dimethyl fumarate; Multiple sclerosis;
Postmarketing; Preclinical; Pregnancy; Safety;
Women
INTRODUCTION
Multiple sclerosis (MS) is a leading cause of
disability in young people and
disproportionately affects women, with
diagnosis often occurring during childbearing
years [1]. Current practice generally advises
women with MS who are planning to become
pregnant to discontinue disease-modifying
treatments (DMTs) before conception [2–4]. In
cases of unintentional pregnancy, exposure to
DMT is highly likely given the recent emphasis
on early treatment and the approval of several
small molecule oral therapies [5, 6]. Yet, little is
known about the safety of oral DMTs during
pregnancy, and information is needed to assist
patients and healthcare providers in weighing
the benefits of remaining on DMT therapy to
control disease activity versus the risk to the
fetus from DMT exposure [2, 6].
Delayed-release dimethyl fumarate (DMF;
also known as gastro-resistant DMF) is a novel
oral agent for the treatment of relapsing forms
of MS [7]. Although the mechanisms by which
DMF exerts its therapeutic effects in MS are
unknown, DMF and its metabolite,
monomethyl fumarate (MMF), have been
shown to activate the nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) pathway,
which is involved in the cellular response to
oxidative stress [8, 9]. In MS clinical trials, DMF
demonstrated efficacy on clinical and
neuroradiological measures, including relapse
rate, sustained disability progression, and lesion
activity on magnetic resonance imaging over
2 years [10, 11]. Adverse events associated with
DMF treatment include flushing;
gastrointestinal events such as nausea,
diarrhea, and abdominal pain; decreases in
white blood cell and lymphocyte counts; and
transient elevation in liver transaminases.
Subjects treated with DMF did not have an
increased risk of infection or malignancy.
Developmental and reproductive toxicology
studies with DMF have been conducted in rats
and rabbits. No formal studies of DMF in
pregnant women have been conducted.
Although recommendations to avoid
pregnancy were in place for patients receiving
DMF in clinical trials, a limited number of
pregnancies occurred. This article provides data
from the preclinical studies and long term
retention as well as outcomes of pregnancies
that occurred during the DMF clinical
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Developmental and reproductive toxicology
studies were performed with DMF.
International Conference on Harmonisation
of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH)
guidelines note that some minimal toxicity is
expected to be induced at a sufficiently high
dose [12]. Embryo-fetal development was
evaluated in Sprague–Dawley rats (n = 25
pregnant females per dose group) and New
Zealand White rabbits (n = 20 pregnant
females per dose group). DMF aqueous
suspension was administered by oral gavage
to rats at doses of 0, 25, 100, and 250 mg/kg
and to rabbits at doses of 0, 25, 75, and
150 mg/kg during the period of organogenesis
(gestation days [GD] 7–18 in rats and GD 7–20
in rabbits). In both studies, maternal animals
were observed for clinical signs, body weight,
and food consumption, and subjected to
laparohysterectomy. The fetuses were assessed
for body weight, sex, and any alterations,
including external, soft tissue, and skeletal
changes. Fetal alterations were evaluated for
malformation (permanent structural change
that is likely to adversely affect the survival
or health of the species) and variation (a
change that occurs within the normal
population under investigation and is
unlikely to adversely affect survival or health)
[13].
Pre- and postnatal development was assessed
in Sprague–Dawley rats (n = 25 pregnant
females per dose group). These animals
received DMF doses at 0, 25, 100, and 250 mg/
kg by oral gavage for 35 days (GD 7 to lactation
day 21). The offspring were assessed for
post-weaning development, sexual maturation,
and reproductive capacity by gross external
examination. Neurobehavioral evaluation
included passive avoidance test (learning,
short-term and long-term retention) and
water-filled M-maze test (overt coordination,
swimming ability, learning, and memory),
which were performed twice separated by
1 week.
Fertility was evaluated in male and female
Sprague–Dawley rats. In the male fertility study,
rats (n = 25 per dose group) received oral DMF
doses of 0, 75, 250, and 375 mg/kg for[70 days
and through cohabitation with naive female
rats. Mating and fertility performance, sperm
evaluation, organ weights, gross necropsy, and
histopathology of selected organs were assessed.
In the female fertility study, rats (n = 25 per
dose group) received oral DMF doses of 0, 25,
100, and 250 mg/kg for 21 days prior to
cohabitation with naive male rats and for up
to GD 7. Study assessments included estrous
cycling, mating and fertility performance, and
gross necropsy.
Juvenile toxicology studies in
Sprague–Dawley rats were conducted that
evaluated potential effects of DMF on growth,
development, reproduction, and neurotoxicity.
Male and female rats received oral DMF at 0, 5,
15, 50, 140, and 375 (males only) mg/kg from
postnatal days (PND) 28 to 92 or 93. Endpoints
applicable to developmental and reproductive
toxicology in these studies were
neurobehavioral assessments (Functional
Observation Battery, Startle Response, Motor
Activity, and Learning and Memory/Biel Maze),
reproductive function (estrous cycling, mating,
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parturition until PND 4, and spermatogenesis),
and histopathological assessment (reproductive
organs and neurological tissues).
Clinical Trials and Postmarketing
Experience
No formal studies of DMF in pregnant women
have been performed. The DMF clinical
development program included healthy
controls and patients with MS, with exposure
to placebo, DMF, or glatiramer acetate (GA),
which was the active comparator in one of the
phase III trials [11].
In the DMF clinical development program,
women who were pregnant, breastfeeding, or
considering becoming pregnant during the
course of the trial were excluded. Pregnancy
was discouraged during the trials, and men and
women of childbearing potential were required
to use effective contraception during the study
period. Urine pregnancy testing was conducted
at regular intervals and study treatment was
discontinued immediately in the event of
pregnancy.
All pregnancies occurring during DMF
clinical trials and their outcomes were
included in this report. Pregnancy outcomes
from the postmarketing setting were also
included. The data cutoff date was June 30,
2014.
Compliance with Ethics Guidelines
All institutional and national guidelines for the
care and use of laboratory animals were
followed. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2013. Informed consent was obtained




There was no evidence of fetal teratogenicity
(malformation) associated with DMF
treatment in rats and rabbits. In female rats,
reduced maternal body weight gain and
maternal food consumption, satisfying the
requirement to assess fetal toxicity in the
context of some maternal toxicity according
to regulatory guidelines [12], were
accompanied by lower fetal weight and
higher incidences of fetal variation (reduced
ossification of the metatarsals and hindlimb
phalanges) at the highest dose (250 mg/kg)
compared to the control group (Table 1). The
systemic exposure at 250 mg/kg is
approximately 11-fold the human therapeutic
dose based on area under the curve (AUC).
The delay in skeletal ossification of forelimb
and hindlimb phalanges has been shown to
be dependent on low fetal body weight in rats
[14, 15]. With additional days of postnatal
development, these bones would likely be
fully ossified. These fetal effects were
considered secondary to maternal toxicity
from intolerability to the high-dose DMF
suspension and were not expected to affect
offspring growth or survival.
In rabbits, significantly reduced food
consumption and corresponding low maternal
body weight gain, satisfying the requirement to
assess fetal toxicity in the context of some
maternal toxicity according to ICH guidelines
[12], led to increased abortion rate (20%; 4 of 20
rabbits) at the highest dose (150 mg/kg),
approximately equivalent to 16 times the
human therapeutic dose of 480 mg/day based
96 Neurol Ther (2015) 4:93–104
on AUC. Low food consumption has been
shown to induce abortions in rabbits [16–19].
The four rabbits with abortions consumed the
lowest amount of food (\10 g/day on most
days) during the treatment.
Maternal reductions in body weight gain
were seen with high-dose DMF in the pre- and
postnatal rat developmental study. Offspring
body weight was significantly reduced at the
highest DMF dose, followed by significantly
delayed sexual maturation in males
(balanopreputial separation). DMF had no
effects on learning or short- or long-term
retention in memory in the passive avoidance
water-maze tests. This was further supported by
the reproductive evaluation in the juvenile
toxicology study in rats in which there were
also no effects on startle responsiveness, motor
activity, learning and memory, and functional
observational battery. In addition,
reproduction, including mating, fertility,
copulation, conception, gestation length,
estrous cyclicity, the process of parturition,
spermatogenesis (concentration, morphology,
and motility), histopathology of reproductive
and neurological organs, and the growth,
survival, and clinical condition of their pups
(up to PND 4) were also unaffected.
There was no evidence that DMF impaired
fertility in male or female rats. In males,
minimal or mild interstitial (Leydig) cell
hyperplasia in the testis was observed with all
doses but had no effect on fertility.
Pharmaceutical and non-pharmaceutical
agents that cause Leydig cell changes in rats
are common and have a low human relevance
[20–22]. The number of non-motile sperm was
slightly higher in the 375-mg/kg group
compared to the control group; this finding
was not statistically significant and considered
Table 1 Maternal body weight changes, fetal body weight differences, and skeletal ossiﬁcation variations in the embryo/fetal
















0 89.1 5.45 4.87 6.32 –
25 -1.8 ?1.7 4.85 6.46 1-fold
100 -17.3** ?0.9 4.83 6.36 4-fold
250 -62.3** -8.3** 4.43** 5.47* 11-fold
* P\0.05 compared to mean control group value
** P\0.01 compared to mean control group value
a Delayed-release DMF (also known as gastro-resistant DMF); DMF dimethyl fumarate
b Body weight gain during the dosing period gestation days 7–17
c For controls, group mean is shown. For treated groups, percentage difference from control values are shown. Statistical
signiﬁcance is based on actual data (not on the percent difference)
d Mean number of bones with ossiﬁcation per fetus per litter
e Exposure margin ratios calculated based on human area under the curve exposure from United States Package Insert
(USPI)
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inconsequential based on a normal number of
motile sperm and lack of effect on fertility. In
females, reductions in body weight gain and
food consumption and disruption of estrous
cycling (prolonged diestrous stage) in 5 of 25
rats were observed at the highest dose (250 mg/
kg) of DMF but without consequent effect on
fertility.
Pregnancy Outcomes in Clinical Trials
As of March 26, 2014, the DMF clinical
development program included 2898 patients
with MS, 320 patients with psoriasis, 101
patients with rheumatoid arthritis, and 813
healthy volunteers, who were exposed to
placebo, DMF, or GA. As of June 30, 2014, a
total of 63 pregnancies were reported in clinical
studies, including 42 in subjects exposed to
DMF, 13 in subjects exposed to placebo, 4 in
subjects exposed to GA, 1 in a patient who
received blinded therapy, and 3 in subjects
whom had discontinued DMF for more than
60 days at the time of their last menstrual
period (LMP; Table 2). Outcomes are known
for 39 of 42 pregnancies in subjects exposed to
DMF, all 13 pregnancies in subjects exposed to
placebo, 3 of 4 pregnancies in subjects exposed
to GA, and one of three pregnancies where DMF
was discontinued for more than 60 days at the
time of their LMP.
The proportion of pregnancies with known
outcomes that resulted in live births was similar
in subjects exposed to DMF (n = 26/39; 67%) or
placebo (9/13; 69%). Of the 26 live births in
subjects exposed to DMF, 22 were full-term
(C37 weeks gestation), 2 were premature
(33–36 weeks gestation), and in 2 cases the
gestational age at birth was unknown. In most
cases, the gestational age at last dose of DMF
was 3–5 weeks. Of the 3 subjects whom had
discontinued DMF for more than 60 days at the
time of their LMP, 1 pregnancy resulted in a
premature (35 weeks) live birth.
Table 2 Pregnancy outcomes from clinical trials as of June 30, 2014







Total number of women who became
pregnant
13 42c 4 1 3 63
Live birth 9 26 1 0 1 37
Spontaneous abortion 2 3d 0 0 0 5
Elective termination 2 10e 2 0 0 14
Pregnancy ongoing 0 2 0 1 2 5
Lost to follow-up 0 1 1 0 0 2
a Delayed-release DMF (also known as gastro-resistant DMF); DMF dimethyl fumarate
b Subjects had discontinued DMF for[60 days at the time of their last menstrual period
c Patients from the pregnancy registry are not included in this analysis
d One subject who had a spontaneous abortion at 11 weeks gestational age had discontinued DMF 240 mg three times a
day 4 months earlier and was taking interferon beta-1a until 6 weeks gestational age
e One elective termination was in the setting of abnormalities detected on ultrasound at least 1 month after the patient
discontinued DMF
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Spontaneous abortions occurred in 3/39
pregnancies with known outcomes (8%) in
subjects exposed to DMF and in 2/13
pregnancies with known outcomes (15%) in
placebo recipients. These spontaneous
abortions occurred early during the first
trimester (gestation B12 weeks). One of the
spontaneous abortions occurred at 11 weeks
gestational age. The patient discontinued DMF
and then received interferon beta-1a as rescue
therapy until an estimated gestational age of
6 weeks; DMF three times daily (TID) was
discontinued 4 months prior to the
spontaneous abortion. This event was
considered by the investigator to be unrelated
to DMF. Another spontaneous abortion
occurred at 9 weeks gestational age in a subject
exposed to DMF TID at the time of conception
and was considered by the investigator to
possibly be related to DMF treatment. This
subject received her last dose of DMF TID
within 30 days of her LMP. The third
spontaneous abortion occurred at 10 weeks
gestational age in a subject who discontinued
DMF at 6 weeks gestation; the event was
considered unrelated to treatment. Elective
terminations were reported for 10/39 (26%)
pregnancies in subjects exposed to DMF twice
daily and 2/13 (15%) pregnancies in placebo
recipients. One elective termination was due to
the detection of triploidy by ultrasound. This
patient discontinued DMF at least 1 month
prior to her LMP. In the four subjects exposed
to GA, one live birth and two elective
terminations were reported; one patient was
lost to follow-up.
Postmarketing Experience
As of June 30, 2014, 135 pregnancies were
reported in the postmarketing setting with
DMF. Of these, 104 were spontaneous reports
and 31 were solicited reports (Table 3).
Pregnancy is ongoing in 103 of these cases and
two patients were lost to follow-up; 10 live
births, 13 spontaneous abortions, and 5 elective
terminations were reported. One case of elective
termination with fetal defects occurred in a
female patient of advanced maternal age
(39 years) and with a previous history of two
full-term births and one miscarriage. The fetal
defects on ultrasound were suggestive of caudal
regression (rudimentary single, fused, short
lower extremity), which is not consistent with
results from animal studies that showed fetal rat
development ossification delay related to
decreased maternal nutritional status at a DMF
dose approximately 11 times the human
therapeutic dose. Of note, the patient had
discontinued DMF 4 weeks after her last LMP,
2 weeks after conception. Development of the
caudal region starts on GD 23–25, and given the
short half-life of DMF, it is unlikely that DMF
was present in the patient’s system to impact
the developing cauda of the fetus [23, 24].
Additional investigation of this case is ongoing
to determine folic acid and diabetes status as
potential confounding factors in fetal defects.
DISCUSSION
Relapsing MS afflicts more females, with an
incidence at least threefold higher than that in
males, and is typically diagnosed between the
ages of 20 and 40 years [1]. Hence, there is a
need for effective MS treatments that are safe for
use in women of childbearing age. In the
absence of formal studies in pregnant women,
information on the safety of MS
disease-modifying therapies during pregnancy
comes from preclinical studies in nonhuman
animals, outcomes of pregnancies occurring
during clinical trials, and postmarketing
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pregnancy registries. This publication provides
information regarding the safety of DMF in
pregnancy.
In preclinical studies, there was no evidence
of fetal malformations associated with
administration of DMF. Fetal variations were
observed only at maternally toxic doses of DMF
and included lower fetal weight and reduced
ossification. Maternal reductions in body
weight and weight gain were seen with
high-dose DMF in the pre- and postnatal rat
study. Offspring body weight was significantly
reduced at the highest DMF dose, followed by
delayed sexual maturation in males only. There
were no effects observed in neurobehavior in
rats. In addition, there was no evidence that
DMF impaired fertility in male or female rats.
DMF received a pregnancy category C rating
from the US Food and Drug Administration [7].
This classification is based on the lack of
adequate and well-controlled studies in
pregnant women and because of the fetal
variations on growth and sexual maturation
observed in animals. Pregnancy category C
indicates that DMF should be used during
pregnancy only if there is a clear need for MS
treatment and the potential benefit justifies the
potential risk to the fetus. Reports of data on
exposure to MS therapeutics in pregnant
women are the best available evidence on the
effects of the drug in pregnancy because
controlled studies are not conducted in
pregnant women.
In the DMF clinical development program,
42 pregnancies occurred in patients exposed to
DMF. While data are limited, there is currently
no evidence of an increased risk of fetal
abnormalities or adverse pregnancy outcomes
associated with exposure to DMF during the
first trimester. The proportion of pregnancies
resulting in live births was similar in subjects
exposed to DMF compared with those receiving
Table 3 Pregnancy outcomes in the postmarketing setting as of June 30, 2014
Pregnancy outcome DMFa (spontaneous reportsb) DMFa (solicited reportsc) Total
Total number of women who became pregnant 104 31 135
Live birth 5 5 10
Spontaneous abortion 11 2 13
Ectopic pregnancy 0 2 2
Elective termination 4 1d 5
Pregnancy ongoing 83 20 103
Lost to follow-up 1 1 2
a Delayed-release DMF (also known as gastro-resistant DMF); DMF dimethyl fumarate
b Spontaneous postmarketing reports
c Solicited postmarketing reports from Tecﬁdera Monitored Therapy Program
d There was one case of elective termination with fetal defects in a female patient of advanced maternal age (39 years) and
with a previous history of two full-term births and one miscarriage. The fetal defects on ultrasound were suggestive of caudal
regression (rudimentary single, fused, short lower extremity), which is not consistent with results from animal studies that
showed fetal rat limb development ossiﬁcation delay related to decreased maternal nutritional status at a DMF dose
approximately 11 times the human therapeutic dose. Of note, the patient had stopped taking DMF 2 weeks after becoming
pregnant, which is prior to the development of the caudal region in humans (gestation days 23–25) [20]
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placebo, and the incidence of spontaneous
abortion was consistent with the expected rate
of early pregnancy loss in the general
population (12–22%) [25]. Outcome is not yet
known for four additional pregnancies from the
clinical studies and for the majority of cases
reported in the postmarketing setting. In
addition, an observational patient registry
(ClinicalTrials.gov identifier, NCT01911767)
has been established to prospectively evaluate
pregnancy outcomes in women with MS who
are exposed to DMF at any time during
pregnancy. Approximately, 310–375 pregnant
women exposed to DMF will be enrolled to
observe 300 prospective pregnancy outcomes.
Fetal outcomes will be monitored for
spontaneous abortions, birth defects, and
other pregnancy and infant outcomes during
pregnancy and for up to 12 weeks after delivery.
Until recently, therapies for MS were
recombinant proteins that required parenteral
administration [2, 5]. The approval of oral
agents may increase compliance and the
incidence of unintentional pregnancy during
therapy [2]. Of currently available oral therapies
for MS, fingolimod is classified pregnancy
category C and teriflunomide is classified
pregnancy category X, thus contraindicated in
pregnancy due to the potential for fetal harm
[26, 27]. Outcomes data for 66 pregnancies with
exposure to fingolimod were reported and
showed evidence of abnormal fetal
development in 5 cases [28]. Although the
sample size is small, these data are consistent
with animal studies and the product labeling
indicating that women of childbearing
potential should be advised to take effective
contraceptive measures during fingolimod
therapy [26, 28].
Interferon-beta has been associated with
decreased mean birth weight and preterm
delivery in some studies, but not low birth
weight (\2500 g), cesarean delivery,
spontaneous abortion, or congenital anomaly;
however, evidence is conflicting [29–33].
Information on birth weight and delivery
(vaginal versus cesarean) was not gathered
during the DMF clinical development
program; thus, the available data do not allow
assessment of the effect of DMF on birth weight
or delivery. Also, the majority of data in this
report originates from subjects enrolled in
clinical trials and may not be representative of
the general population of people with MS.
CONCLUSIONS
Animal studies showed no evidence of
teratogenicity or impaired fertility with
exposure to DMF at doses that caused
maternal effects. Although data are limited,
there is no evidence to date of an increased
risk of fetal abnormalities or adverse pregnancy
outcomes associated with gestational exposure
to DMF during the first trimester. Additionally,
the incidence of spontaneous abortion was
consistent with that reported in the general
population. However, while the limited data
here does not indicate an increased risk, there
are no adequate and well-controlled studies
among pregnant women exposed to DMF. In
animals, adverse effects on offspring survival,
growth, sexual maturation, and
neurobehavioral function were observed when
DMF was administered during pregnancy and
lactation at clinically relevant doses. Therefore,
as a pregnancy category C drug, regulators
advise that DMF should be used during
pregnancy only if the potential benefit justifies
the potential risk to the fetus. A pregnancy
registry has been established to monitor
pregnancy outcomes in subjects receiving DMF.
Neurol Ther (2015) 4:93–104 101
ACKNOWLEDGMENTS
This study and the article processing charges for
this publication were funded by Biogen, Inc.
The authors would like to acknowledge Janet
Clarke, PhD (formerly of Biogen) for
contributing to the preclinical toxicology
study designs and interpretation of the data.
Karyn M. Myers, PhD, of Biogen and Michelle
McDermott, PharmD, provided writing support
based on input from authors. Biogen reviewed
and provided feedback on the paper to the
authors. The authors had full editorial control
of the paper and provided their final approval of
all content. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval for the version to be published.
Disclosures. Ralf Gold has received
honoraria from Bayer HealthCare, Biogen,
Merck Serono, Novartis, and Teva
Neuroscience; research support from Bayer
HealthCare, Biogen, Merck Serono, Novartis,
and Teva Neuroscience; and compensation
from Sage for serving as editor of Therapeutic
Advances in Neurological Disorders. J. Theodore
Phillips has received consulting or speaking
honoraria from Acorda, Biogen, Genzyme,
Sanofi, and Xenoport, and research grant
funding from Roche and Biogen. Eva
Havrdova has received honoraria from Bayer,
Biogen, Genzyme, GlaxoSmithKline, Merck
Serono, Novartis, Sanofi, and Teva; research
support from Biogen; and support by research
project of Czech Ministry of Education
PRVOUK-P26/LF1/4. Amit Bar-Or has received
honoraria and/or research support from
Amplimmune, Aventis, Bayhill Therapeutics,
Berlex, Biogen, Diogenix, Eli-Lilly, EMD
Serono, Genentech, GlaxoSmithKline,
Medimmune, Novartis, Ono Pharma, Receptos,
Roche, Sanofi Genzyme, and Teva
Neuroscience. Ludwig Kappos has received
research support from Actelion, Allozyne,
BaroFold, Bayer HealthCare, Bayer Schering,
Bayhill Therapeutics, Biogen, Boehringer
Ingelheim, Eisai, Elan, European Union,
Genmab, Genzyme, GlaxoSmithKline,
Glenmark, MediciNova, Merck Serono,
Mitsubishi, Novartis, Novartis Research
Foundation, Roche, Roche Research
Foundation, Sanofi-Aventis, Santhera, Swiss
MS Society, Swiss National Research
Foundation, and Teva Neuroscience. Huixing
Yuan, Patricia Valencia, Lauren Oliva, Mark
Novas, Jie Li, Nuwan Kurukulasuriya, Norman
Kim, Tim Thullen, and Vissia Viglietta are
employees of and own stock/stock options in
Biogen, Inc. Marianne T. Sweetser is an
employee of Alnylam Pharmaceuticals, Inc.
and was formerly employed at Biogen, Inc.
and owns stock in Biogen, Inc. Robert J. Fox has
received consultant fees from Allozyne, Avanir,
Biogen, Novartis, Questcor, Teva, and
Xenoport; served on advisory committees for
Biogen and Novartis; research grant funding
from Novartis.
Compliance with ethics guidelines. All
institutional and national guidelines for the
care and use of laboratory animals were
followed. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
102 Neurol Ther (2015) 4:93–104
Open Access. This article is distributed under
the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit to
the original author(s) and the source, provide a
link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Tullman MJ. Overview of the epidemiology,
diagnosis, and disease progression associated with
multiple sclerosis. Am J Manag Care.
2013;19:S15–20.
2. Lu E, Wang BW, Synnes A, Dahlgren L, Sadovnick
AD, Tremlett H. A review of safety-related
pregnancy data surrounding the oral
disease-modifying drugs for multiple sclerosis.
CNS Drugs. 2014;28:89–94.
3. Lu E, Wang BW, Guimond C, et al. Safety of
disease-modifying drugs for multiple sclerosis in
pregnancy: current challenges and future
considerations for effective pharmacovigilance.
Expert Rev Neurother. 2013;13(3):251–61.
4. Coyle PK, Christie S, Fodor P, et al. Multiple
sclerosis gender issues: clinical practices of women
neurologists. Mult Scler. 2004;10:582–8.
5. Langer-Gould AM. The pill times 2: what every
woman with multiple sclerosis should know.
Neurology. 2014;82:1–2.
6. Fragoso YD, Boggild M, Macias-Islas MA, et al. The
effects of long-term exposure to disease-modifying
drugs during pregnancy in multiple sclerosis. Clin
Neurol Neurosurg. 2013;115:154–9.
7. Tecfidera (dimethyl fumarate) prescribing
information. Cambridge: Biogen Inc.; 2013. http://
www.tecfidera.com/pdfs/full-prescribing-information.
pdf. Accessed Oct 21, 2014.
8. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters
exert neuroprotective effects in neuroinflammation
via activation of the Nrf2 antioxidant pathway.
Brain. 2011;134:678–92.
9. Scannevin RH, Chollate S, Jung MY, et al.
Fumarates promote cytoprotection of central
nervous system cells against oxidative stress via
the nuclear factor (erythroid-derived 2)-like 2
pathway. J Pharmacol Exp Ther. 2012;341:274–84.
10. Gold R, Kappos L, Arnold DL, et al.
Placebo-controlled phase 3 study of oral BG-12 for
relapsing multiple sclerosis. N Engl J Med.
2012;367(12):1098–107.
11. Fox RJ, Miller DH, Phillips T, et al.
Placebo-controlled phase 3 study of oral BG-12 or
glatiramer in multiple sclerosis. N Engl J Med.
2012;367(12):1087–97.
12. International Conference on Harmonisation [ICH]
S5(R2) guideline: Detection of Toxicity to
Reproduction for Medicinal Products & Toxicity to
Male Fertility, current Step 4 version. 2005.
13. Chahoud I, Buschmann J, Clark R, et al.
Classification terms in developmental toxicology:
need for harmonization. Report of the second
workshop on the terminology in developmental
toxicology. Reprod Toxicol. 1999;13(1):77–82.
14. Chahoud I, Paumgartten FJR. Relationships
between fetal body weight of Wistar rats at term
and the extent of skeletal ossification. Braz J Med
Biol Res. 2005;38:565–75.
15. Carney EW, Kimmel CA. Interpretation of skeletal
variations for human risk assessment: delayed
ossification and wavy ribs. Birth Defects Res B Dev
Reprod Toxicol. 2007;80(6):473–96.
16. Matsuzawa T, Nakata M, Goto I, Tsushima M.
Dietary deprivation induces fetal loss and abortion
in rabbits. Toxicology. 1981;22(3):255–9.
17. Clark RL, Antonello JM, Wenger JD, Deverle-Brooks
K, Duchai DM. Selection of food allotment for New
Zealand white rabbits in developmental toxicity
studies. Fundam Appl Toxicol. 1991;17(3):584–92.
18. Matsuoka T, Mizoguchi Y, Serizawa K, Ishikura T,
Mizuguchi H, Asano Y. Effects of stage and degree of
restricted feeding on pregnancy outcome in rabbits.
J Toxicol Sci. 2006;31(2):169–75.
19. Cappon GD, Fleeman TL, Chapin RE, Hurtt ME.
Effects of feed restriction during organogenesis on
embryo-fetal development in rabbit. BDR(B).
2006;74:424–30.
20. Prentice DE, Meikle AW. A review of drug-induced
Leydig cell hyperplasia and neoplasia in the rat and
some comparisons with man. Hum Exp Toxicol.
1995;14(7):562–72.
Neurol Ther (2015) 4:93–104 103
21. Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM,
Foster PM. Rodent Leydig cell tumorigenesis: a
review of the physiology, pathology, mechanisms,
and relevance to humans. Crit Rev Toxicol.
1999;29(2):169–261.
22. Clegg ED, Cook JC, Chapin RE, Foster PM, Daston
GP. Leydig cell hyperplasia and adenoma
formation: mechanisms and relevance to humans.
Reprod Toxicol. 1997;11(1):107–21.
23. Zaw W, Stone DG. Caudal regression syndrome in
twin pregnancy with type II diabetes. J Perinatol.
2002;22(2):171–4.
24. Litjens NH, van Strijen E, van Gulpen C, et al.
In vitro pharmacokinetics of anti-psoriatic fumaric
acid esters. BMC Pharmacol. 2004;4:22. doi:10.
1186/1471-2210-4-22.
25. Garcı´a-Enguı´danos A, Calle ME, Valero J, Luna S,
Domı´nguez-Rojas V. Risk factors in miscarriage: a
review. Eur J Obstet Gynecol Reprod Biol.
2002;102(2):111–9.
26. Gilenya (fingolimod) prescribing information. East
Hanover: Novartis International AG; 2014. http://
www.pharma.us.novartis.com/product/pi/pdf/
gilenya.pdf. Accessed Oct 21, 2014.
27. Aubagio (teriflunomide) prescribing information.
Cambridge: Genzyme Corporation, a Sanofi
company; 2012. http://products.sanofi.us/aubagio/
aubagio.pdf. Accessed Oct 21, 2014.
28. Karlsson G, Francis G, Koren G, et al. Pregnancy
outcomes in the clinical development program of
fingolimod in multiple sclerosis. Neurology.
2014;82:674–80.
29. Weber-Schoendorfer C, Schaefer C. Multiple
sclerosis, immunomodulators, and pregnancy
outcome: a prospective observational study. Mult
Scler. 2009;15:1037–42.
30. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy
and fetal outcomes after interferon-b exposure in
multiple sclerosis. Neurology. 2010;75:1794–802.
31. Houtchens MK, Kolb CM. Multiple sclerosis and
pregnancy: therapeutic considerations. J Neurol.
2013;260:1202–14.
32. Dahl J, Myhr KM, Daltveit AK, Gilhus NE.
Pregnancy, delivery and birth outcome in
different stages of maternal multiple sclerosis.
J Neurol. 2008;255(6):623–7.
33. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick
D, Tremlett H. Disease-modifying drugs for
multiple sclerosis in pregnancy: a systematic
review. Neurology. 2012;79(11):1130–5.
104 Neurol Ther (2015) 4:93–104
